Early ACS
Protocol Number: M-INTG03-062/PO3684
Therapeutic Area: Cardiology
Summary:
To demonstrate the superiority of early eptifibatide, administered as a double bolus plus infusion, compared to placebo (with provisional use of eptifibatide in the catheterization laboratory) in reducing the composite of death, myocardial infarction (MI), recurrent ischemia requiring urgent revascularization (RI-UR), and thrombotic bail-out (TBO).
Inclusion Criteria:
- Experiencing symptoms of cardiac ischemia at rest (angina or angina equivalent) with episode(s) lasting at least 10 minutes within 24 hours of randomization and have at least 2 of the following:
- ST segment changes in at least 2 contiguous leads.
- Positive Cardiac Markers
- > 60 years old
- OR ALL 3 of the Following:
- History MI, PCI, CABG, >50% stenosis, ischemia on stress test, PVD
- Positive Cardiac Markers
- 50-59 Years Old
- Plan to undergo an invasive strategy after administration of study drug for 12 to 96 hours
* Additional Eligibility Criteria Exist *
Center Name: Mercy Research Institute at Mercy Hospital
Contact Information: Mercy Research Institute Clinical Trial Coordinators
Address: 3659 South Miami Avenue, Suite 3001, Miami, Florida 33133
Phone: (305) 854-4400, ext. 2312
Fax: (305) 285-2791
E-mail: rhumphreys@mercymiami.org